Additional Study Information: The main aim of this clinical trial is to know the effects (good or bad) that study drug lurbinectedin (PM01183), has on women with ovarian cancer. Lurbinectedin (PM01183), is an investigational drug. This means that the drug has not been approved by the Food and Drug Administration (FDA) for medical use in patients, but has only been approved for use in research. In this trial, PM01183 is compared to other two common anticancer drugs used as treatment of platinum-resistant ovarian cancer: pegylated liposomal doxorubicin (PLD) and topotecan. The knowledge obtained from this treatment combination will allow fighting against this type of cancer in a more specific way.